ERBB2 and breast cancer: One of the important targets of immunotherapy in HER2-positive BC is the programmedcell death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, which playsan important role in immune system regulation and tumor immune evasion [30].